Caring Ambassadors Hepatitis C Program Newsletter
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Kwo PY, Lawitz EJ, McCone J, et al. Lancet. 2010 Aug 28;376(9742):705-716. Epub 2010 Aug 6.
Is chronic hepatitis C virus infection a risk factor for breast cancer? Larrey D, Bozonnat MC, Kain I, Pageaux GP, Assenat E. World J Gastroenterol. 2010 Aug 7;16(29):3687-91.
Alpha-fetoprotein above normal levels as a risk factor for the development of hepato-cellular carcinoma in patients infected with hepatitis C virus. Tateyama M, Yatsuhashi H, Taura N, et al. J Gastroenterol. 2010 Aug 14. [Epub ahead of print]
Quality of care in patients with chronic hepatitis C virus infection: a cohort study.
Kanwal F, Schnitzler MS, Bacon BR, et al. Ann Intern Med. 2010 Aug 17;153(4):231-9.
HCV treatment-related anemia is associated with higher sustained virologic response rate.
Sulkowski MS, Shiffman ML, Afdhal NH, et al. Gastroenterology. 2010 Aug 16. [Epub ahead of print]
Effects of recognizing depression with a standardized questionnaire (CES-D) versus patient reporting of depression after a single-standardized question on the outcomes of treatment for hepatitis C with pegylated interferon-alpha-2b and ribavirin. Phillips FH, Prebis M, Grumbeck C, et al. Eur J Gastroenterol Hepatol. 2010 Aug 26. [Epub ahead of print]
Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide. Rossignol JF, Elfert A, Keeffe EB. J Clin Gastroenterol. 2010 Aug;44(7):504-9.
Prevalence and impact of manic traits in depressed patients initiating interferon therapy for chronic hepatitis C infection. Lim C, Olson J, Zaman A, Phelps J, Ingram KD. J Clin Gastroenterol. 2010 Aug;44(7):e141-6.
Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection.
Delgado-Borrego A, Healey D, Negre B, et al. J Pediatr Gastroenterol Nutr. 2010 Aug;51 (2):191-7.
Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. Narkewicz MR, Rosenthal P, Schwarz KB, et al. J Pediatr Gastroenterol Nutr. 2010 Aug;51(2):183-6.
Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment. Gerner P, Hilbich J, Wenzl TG, et al. J Pediatr Gastroenterol Nutr. 2010 Aug;51(2):187-90.
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Frey SE, Houghton M, Coates S, et al. Vaccine. 2010 Aug 31;28(38):6367-73. Epub 2010 Jul 7.
Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. Ramos EL. J Interferon Cytokine Res. 2010 Aug;30(8):591-5.
The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Broering R, Zhang X, Kottilil S, et al. Gut. 2010 Aug;59(8):1111-9.
New NS5B polymerase inhibitors for hepatitis C. Legrand-Abravanel F, Nicot F, Izopet J. Expert Opin Investig Drugs. 2010 Aug;19(8):963-75.
Sensory neuropathy in patients with cryoglobulin negative hepatitis-C infection.
Yoon MS, Obermann M, Dockweiler C, et al. J Neurol. 2010 Aug 4. [Epub ahead of print]
Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.
Asahina Y, Tsuchiya K, Tamaki N, et al. Hepatology. 2010 Aug;52(2):518-27.
Predictors of Early Treatment Discontinuation Among Patients with Genotype 1 Hepatitis C and Implications for Viral Eradication. Beste LA, Ioannou GN, Larson M, Chapko M, Dominitz JA. Clin Gastroenterol Hepatol. 2010 Aug 5. [Epub ahead of print]
Impact of IL28B genotype on the early and sustained virologic response in treatment-naďve patients with chronic hepatitis C. Stättermayer AF, Stauber R, Hofer H, et al. Clin Gastroenterol Hepatol. 2010 Aug 19. [Epub ahead of print]
Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C. Sanjo M, Saito T, Ishii R, et al. J Med Virol. 2010 Aug;82(8):1364-70.
Hepatocellular carcinoma in individuals with HBV infection or HBV-HCV co-infection in a low endemic country. Davídsdóttir L, Duberg AS, Törner A, et al. Scand J Gastroenterol. 2010 Aug;45(7-8):944-52.
Development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gentile I, Borgia G. Expert Rev Anti Infect Ther. 2010 Aug;8(8):867-70.
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
Leutscher PD, Lagging M, Buhl MR, et al. Hepatology. 2010 Aug;52(2):430-5.
Effect of HCV infection on the mRNA expression of drug transporters and cytochrome P450 enzymes in chimeric mice with humanized liver. Kikuchi R, McCown M, Olson P, et al. Drug Metab Dispos. 2010 Aug 6. [Epub ahead of print]
c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. Machida K, Tsukamoto H, Liu JC, et al. Hepatology. 2010 Aug;52(2):480-92.
Ultrastructural and biophysical characterization of hepatitis c virus particles produced in cell culture. Gastaminza P, Dryden K, Boyd B, Wood M, Law M, Yeager M, Chisari FV. J Virol. 2010 Aug 4. [Epub ahead of print]
Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast. Cai W, Su L, Liao Q, Ye L, Wu Y, Wu Z, She Y. Antiviral Res. 2010 Aug 5. [Epub ahead of print]
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
Akuta N, Suzuki F, Hirakawa M, et al. Hepatology. 2010 Aug;52(2):421-9.
HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection. Lange CM, Roomp K, Dragan A, et al. J Hepatol. 2010 Aug 3. [Epub ahead of print]
Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Tuyama AC, Hong F, Saiman Y, et al. Hepatology. 2010 Aug;52(2):612-22.
Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? Resino S, Bellon JM, Asensio C, et al. BMC Infect Dis. 2010 Aug 19;10(1):244. [Epub ahead of print]
Similar Progression of Fibrosis between HIV/HCV- and HCV-Infected Patients: Analysis of Paired Liver Biopsy Samples. Sterling RK, Wegelin JA, Smith PG, et al. Clin Gastroenterol Hepatol. 2010 Aug 19. [Epub ahead of print]
Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. Araújo ES, Dahari H, Neumann AU, et al. J Viral Hepat. 2010 Aug 3. [Epub ahead of print]
Relating the liver damage with hepatitis C virus polymorphism in core region and human variables in HIV-1-coinfected patients. Matas M, Picornell A, Cifuentes C, et al. Infect Genet Evol. 2010 Aug 20. [Epub ahead of print]
Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals. Rizza SA, Cummins NW, Rider DN, et al. AIDS. 2010 Aug 26. [Epub ahead of print]
The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infection.
Nischalke HD, Vogel M, Mauss S, et al. AIDS. 2010 Aug 24;24(13):2001-7.
Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. de Castro IF, Micheloud D, Berenguer J, et al. AIDS. 2010 Aug 24;24(13):2059-67.
Clinical and biologic importance of F-actin autoantibodies in HCV monoinfected and HCV-HIV coinfected patients. Hudacko RM, Alvarez GA, Talal AH, et al. Am J Clin Pathol. 2010 Aug;134(2):228-34.
Long-Term Management of Hepatitis C-Seropositive Subjects with AntiOxidant Biofactor (AOB(R)), a Fermented Food Supplement. Myo-Khin, Myat-Tin-Htwe-Kyaw, Yi-Yi-Kyaw, et al. Acta Med Okayama. 2010 Aug;64(4):243-8.
Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication.
Li S, Kodama EN, Inoue Y,et al. Antivir Chem Chemother. 2010 Aug 11;20(6):239-48.
Real-time tissue elastography as a tool for the noninvasive assessment of liver stiffness in patients with chronic hepatitis C. Morikawa H, Fukuda K, Kobayashi S, et al. J Gastroenterol. 2010 Aug 10. [Epub ahead of print]
The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Su J, Brook RA, Kleinman NL, Corey-Lisle P. Hepatology. 2010 Aug;52(2):436-42.
Inflammatory bowel diseases and hepatitis C virus infection. Li YD, Lin JJ, Zheng SS. Hepatobiliary Pancreat Dis Int. 2010 Aug;9(4):398-401.
Prevalence of hepatitis C in two inpatient psychiatry populations. Gunewardene R, Lampe L, Ilchef R. Australas Psychiatry. 2010 Aug;18(4):330-4.
HCC develops even in the early stage of chronic liver disease in elderly patients with HCV infection. Takata A, Kuromatsu R, Ando E, et al. Int J Mol Med. 2010 Aug;26(2):249-56.
Development and evaluation of an automated hepatitis C virus NS5B sequence-based subtyping assay. Koletzki D, Dumont S, Vermeiren H, Fevery B, De Smet P, Stuyver LJ. Clin Chem Lab Med. 2010 Aug;48(8):1095-102.
Survival of Hepatitis C Virus in Syringes: Implication for Transmission among Injection Drug Users. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. J Infect Dis. 2010 Aug 20. [Epub ahead of print]
Tobacco and other factors have a negative impact on quality of life in hepatitis C patients.
Yamini D, Basseri B, Chee GM, et al. J Viral Hepat. 2010 Aug 15. [Epub ahead of print]
Arakelyan A, Enayati P, Tran TT, Poordad F.